{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-048593","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2023-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.102144+00:00","generated_at":"2026-06-10T14:40:13.845861+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kintara Therapeutics FY2023 net loss $14.6M, cash $1.5M; VAL-083 data expected by year-end","bullets":["Net loss $14.6M ($9.27/share) vs $22.7M ($25.80) in FY2022; R&D fell to $9.3M from $15.2M.","Cash and equivalents $1.5M at June 30, 2023, down from $11.8M; working capital $188K.","Awarded $2.0M NIH SBIR grant for REM-001; first patient in 15-patient study expected Q4 2023.","Top-line data from VAL-083 GBM AGILE registrational study anticipated before end of calendar 2023.","General and administrative costs decreased to $5.5M from $7.5M due to reduced staffing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-048593","json":"https://secwatch.observer/filing/0000950170-23-048593.json","markdown":"https://secwatch.observer/filing/0000950170-23-048593.md","text":"https://secwatch.observer/filing/0000950170-23-048593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023048593/0000950170-23-048593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023048593/ktra-20230918.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T14:40:13.845861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"faa3a5f27e9190f12e0bf91aa274f9c97679b4e9","claim":"TuHURA Biosciences, Inc./NV reported the fiscal year ended June 30, 2023 results: net income a net loss of approximately $14.6 million, or $9.27 per share, EPS $9.27 per share.","evidence_excerpt":"For the year ended June 30, 2023, Kintara reported a net loss of approximately $14.6 million, or $9.27 per share, compared to a net loss of approximately $22.7 million, or $25.80 per share, for the year ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023048593/0000950170-23-048593-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended June 30, 2023"},{"label":"Net income","value":"a net loss of approximately $14.6 million, or $9.27 per share"},{"label":"EPS","value":"$9.27 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}